BioSpace News Archive

Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ended June 30, 2021 on Tuesday, July 27, 2021 at 8:00 a.m. EDT .

MedPro Systems and its Compliance Advisory Services team today announced a partnership with PharmaCertify, the compliance training division of NXLevel Solutions, to help Life Sciences organizations implement more effective and cohesive compliance programs.

CrestOptics S.p.A., today announced that it has been selected by Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, as a premier microscope provider to jointly develop new spatial biology and spatial phenotyping applications.

The market is estimated to grow with a CAGR of 8.1% from 2018-2025.

Results from two large clinical trials show significant and early benefits from sotagliflozin, a drug that inhibits sodium-glucose transport protein 2 and sodium-glucose transport protein 1 in reducing heart failure, heart attack, and stroke—major problems in people with diabetes.

OmniVision Technologies, Inc., a leading developer of advanced digital imaging solutions, today announced its next-generation OH08A and OH08B CMOS image sensors―the first 8 megapixel (MP) resolution sensors for single-use and reusable endoscopes.

Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products today announced the successful completion of their final system safety studies and cellular safety assays for entering clinical trials to treat concussion.

Vericel Corporation today announced that its development partner, MediWound Ltd., received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for NexoBrid, a potential treatment for eschar removal in adults with deep partial-thickness and/or full-thickness burns.

MediWound Ltd. today announced it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) seeking approval of NexoBrid ® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.

Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the initiation of the DEFINE AFib study, the company’s first app-based research study.